U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07602088) titled 'A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia' on May 16.
Brief Summary: The purpose of this study is to see how well Ibrutinib and Venetoclax (I+V) treatment works (effectiveness) for participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) when it is used in routine, everyday medical care.
Study Start Date: June 01
Study Type: OBSERVATIONAL
Condition:
Leukemia, Lymphocytic, Chronic, B-Cell
Recruitment Status: RECRUITING
Sponsor: Janssen Research & Development, LLC
Published by HT Digital...